2244440-85-3
2244440-85-3
Chemical Structure
Omesdafexor
Synonym(s): MET409
- CAS. Nr.: 2244440-85-3
- Formula:C34H43N3O3
- Molecular Weight:541.72
IUPAC Name: (((S)-4-carboxy-4-((S)-4-carboxy-4-(6-(4-(fluoro-18F)benzamido)hexanamido)butanamido)butoxy)(hydroxy)phosphoryl)-L-glutamic acid
InChIKey: RPBNLMPTFCTXRQ-RYYHSFPWSA-N
SMILES: CC(C=C1[C@@H](CC2)CC[C@H]2CN(C3=CC(C4=CN(C5CC5)N=C4)=CC=C3)C([C@@H]6CC[C@H](CC6)O)=O)=C(C=C1)OC
Biological Activity: Omesdafexor (MET409) is an orally active FXR agonist with a unique non-bile acid structure. Omesdafexor can be used for the study of non-alcoholic steatohepatitis (NASH)[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Omesdafexor | 99.09% | Omesdafexor (MET409) is an orally active FXR agonist with a unique non-bile acid structure. Omesdafexor can be used for the study of non-alcoholic steatohepatitis (NASH). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. WHO Drug Information, Vol. 36, No. 2, 2022
- [2]. Harrison SA, Bashir MR, Lee KJ, Shim-Lopez J, Lee J, Wagner B, Smith ND, Chen HC, Lawitz EJ. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J Hepatol. 2021 Jul;75(1):25-33. [Content Brief]
Keywords
